SSBP3 Rabbit Polyclonal Antibody – TA333761 | Origene

Total Page：16

File Type：pdf, Size：1020Kb

SSBP3 Rabbit Polyclonal Antibody – TA333761 | Origene

OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA333761 SSBP3 Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: WB Recommended Dilution: WB Reactivity: Human Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: The immunogen for Anti-SSBP3 Antibody: synthetic peptide directed towards the middle region of human SSBP3. Synthetic peptide located within the following region: SNFPMGPGSDGPMGGMGGMEPHHMNGSLGSGDIDGLPKNSPNNISGISNP Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Note that this product is shipped as lyophilized powder to China customers. Purification: Affinity Purified Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 38 kDa Gene Name: single stranded DNA binding protein 3 Database Link: NP_060540 Entrez Gene 23648 Human Q9BWW4 Background: SSBP3 may be involved in transcription regulation of the alpha 2(I) collagen gene where it binds to the single-stranded polypyrimidine sequences in the promoter region. Synonyms: CSDP; SSDP; SSDP1 Note: Immunogen sequence homology: Dog: 100%; Pig: 100%; Rat: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rabbit: 100%; Guinea pig: 100%; Bovine: 93%; Zebrafish: 93% This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 SSBP3 Rabbit Polyclonal Antibody – TA333761 Protein Families: Transcription Factors Product images: WB Suggested Anti-SSBP3 Antibody Titration: 0.2- 1 ug/ml; ELISA Titer: 1: 312500; Positive Control: Jurkat cell lysateSSBP3 is supported by BioGPS gene expression data to be expressed in Jurkat This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 2 / 2.

Copy Link

Recommended publications

Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
[Show full text]
Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
[Show full text]
(Proper, Insufficient, Aberrant, and NO Reprogramming) Response to the Yamanaka Factors in the Initial Stages of Human I
International Journal of Molecular Sciences Article A PIANO (Proper, Insufficient, Aberrant, and NO Reprogramming) Response to the Yamanaka Factors in the Initial Stages of Human iPSC Reprogramming Kejin Hu Department of Biochemistry and Molecular Genetics, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA; [email protected] Received: 7 April 2020; Accepted: 29 April 2020; Published: 2 May 2020 Abstract: Yamanaka reprogramming is revolutionary but inefficient, slow, and stochastic. The underlying molecular events for these mixed outcomes of induction of pluripotent stem cells (iPSC) reprogramming is still unclear. Previous studies about transcriptional responses to reprogramming overlooked human reprogramming and are compromised by the fact that only a rare population proceeds towards pluripotency, and a significant amount of the collected transcriptional data may not represent the positive reprogramming. We recently developed a concept of reprogramome, which allows one to study the early transcriptional responses to the Yamanaka factors in the perspective of reprogramming legitimacy of a gene response to reprogramming. Using RNA-seq, this study scored 579 genes successfully reprogrammed within 48 h, indicating the potency of the reprogramming factors. This report also tallied 438 genes reprogrammed significantly but insufficiently up to 72 h, indicating a positive drive with some inadequacy of the Yamanaka factors. In addition, 953 member genes within the reprogramome were transcriptionally irresponsive to reprogramming, showing the inability of the reprogramming factors to directly act on these genes. Furthermore, there were 305 genes undergoing six types of aberrant reprogramming: over, wrong, and unwanted upreprogramming or downreprogramming, revealing significant negative impacts of the Yamanaka factors. The mixed findings about the initial transcriptional responses to the reprogramming factors shed new insights into the robustness as well as limitations of the Yamanaka factors.
[Show full text]
Genomic Landscape of Paediatric Adrenocortical Tumours
ARTICLE Received 5 Aug 2014 | Accepted 16 Jan 2015 | Published 6 Mar 2015 DOI: 10.1038/ncomms7302 Genomic landscape of paediatric adrenocortical tumours Emilia M. Pinto1,*, Xiang Chen2,*, John Easton2, David Finkelstein2, Zhifa Liu3, Stanley Pounds3, Carlos Rodriguez-Galindo4, Troy C. Lund5, Elaine R. Mardis6,7,8, Richard K. Wilson6,7,9, Kristy Boggs2, Donald Yergeau2, Jinjun Cheng2, Heather L. Mulder2, Jayanthi Manne2, Jesse Jenkins10, Maria J. Mastellaro11, Bonald C. Figueiredo12, Michael A. Dyer13, Alberto Pappo14, Jinghui Zhang2, James R. Downing10, Raul C. Ribeiro14,* & Gerard P. Zambetti1,* Paediatric adrenocortical carcinoma is a rare malignancy with poor prognosis. Here we analyse 37 adrenocortical tumours (ACTs) by whole-genome, whole-exome and/or transcriptome sequencing. Most cases (91%) show loss of heterozygosity (LOH) of chromosome 11p, with uniform selection against the maternal chromosome. IGF2 on chromosome 11p is overexpressed in 100% of the tumours. TP53 mutations and chromosome 17 LOH with selection against wild-type TP53 are observed in 28 ACTs (76%). Chromosomes 11p and 17 undergo copy-neutral LOH early during tumorigenesis, suggesting tumour-driver events. Additional genetic alterations include recurrent somatic mutations in ATRX and CTNNB1 and integration of human herpesvirus-6 in chromosome 11p. A dismal outcome is predicted by concomitant TP53 and ATRX mutations and associated genomic abnormalities, including massive structural variations and frequent background mutations. Collectively, these ﬁndings demonstrate the nature, timing and potential prognostic signiﬁcance of key genetic alterations in paediatric ACT and outline a hypothetical model of paediatric adrenocortical tumorigenesis. 1 Department of Biochemistry, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA. 2 Department of Computational Biology and Bioinformatics, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA.
[Show full text]
Discovery of a Role for Rab3b in Habituation and Cocaine Induced Locomotor Activation in Mice Using Heterogeneous Functional
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.21.048405; this version posted April 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 2 3 4 Discovery of a role for Rab3b in habituation and cocaine induced 5 locomotor activation in mice using heterogeneous functional genomic analysis 6 7 8 9 Jason A. Bubier1# ,Vivek M. Philip1#, Price E. Dickson1, Guy Mittleman2, Elissa J. Chesler1 10 1The Jackson Laboratory, Bar Harbor, ME 11 2Ball State University, Muncie, IN 12 13 # Equally contributing 1st authors 14 Corresponding Author: 15 Elissa J. Chesler 16 The Jackson Laboratory 17 600 Main Street 18 Bar Harbor ME 04609 19 RUNNING TITLE: Rab3b influences habituation & locomotor response to cocaine 20 KEYWORDS: Genetic, QTL, genomics, cocaine sensitization, habituation 21 22 Guidelines (Max. Limits) 23 Abstract length: 350 words =262 24 Figures and tables: 15 25 Manuscript length: 12000 words 26 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.21.048405; this version posted April 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 27 Author Contributions: 28 JAB, VMP, GM, EJC Conception or design of the work. JAB, VMP, GM Data collection. 29 JAB, VMP, PED, EJC , Data analysis and interpretation JAB, VMP, PED, EJC Drafting 30 and revising the article. JAB, VMP, PED, GM, EJC Final approval of the version to be 31 published.
[Show full text]
Single-Stranded DNA Binding Protein Ssbp3 Induces Differentiation Of
Liu et al. Stem Cell Research & Therapy (2016) 7:79 DOI 10.1186/s13287-016-0340-1 RESEARCH Open Access Single-stranded DNA binding protein Ssbp3 induces differentiation of mouse embryonic stem cells into trophoblast-like cells Jifeng Liu1, Xinlong Luo1,3, Yanli Xu1, Junjie Gu1,2, Fan Tang1,2, Ying Jin1,2* and Hui Li1,2* Abstract Background: Intrinsic factors and extrinsic signals which control unlimited self-renewal and developmental pluripotency in embryonic stem cells (ESCs) have been extensively investigated. However, a much smaller number of factors involved in extra-embryonic trophoblast differentiation from ESCs have been studied. In this study, we investigated the role of the single-stranded DNA binding protein, Ssbp3, for the induction of trophoblast-like differentiation from mouse ESCs. Methods: Gain- and loss-of-function experiments were carried out through overexpression or knockdown of Ssbp3 in mouse ESCs under self-renewal culture conditions. Expression levels of pluripotency and lineage markers were detected by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analyses. The global gene expression profile in Ssbp3-overexpressing cells was determined by affymetrix microarray. Gene ontology and pathway terms were analyzed and further validated by qRT-PCR and Western blotting. The methylation status of the Elf5 promoter in Ssbp3-overexpressing cells was detected by bisulfite sequencing. The trophoblast-like phenotype induced by Ssbp3 was also evaluated by teratoma formation and early embryo injection assays. Results: Forced expression of Ssbp3 in mouse ESCs upregulated expression levels of lineage-associated genes, with trophoblast cell markers being the highest. In contrast, depletion of Ssbp3 attenuated the expression of trophoblast lineage marker genes induced by downregulation of Oct4 or treatment with BMP4 and bFGF in ESCs.
[Show full text]
Original Article Integrative Analysis of Somatic Mutations and Differential Expression Profiles in Glioblastoma Based on Aging Acceleration
Int J Clin Exp Pathol 2021;14(5):582-595 www.ijcep.com /ISSN:1936-2625/IJCEP0121428 Original Article Integrative analysis of somatic mutations and differential expression profiles in glioblastoma based on aging acceleration Huize Wang1,2, Shiyan Li3, Hongxin Liu3, Shiyu Bian4, Wanjiang Huang5, Chengzhong Xing2, Yin Wang2,3 1Department of Nursing, First Affiliated Hospital of China Medical University, 155# North Nanjing Street, Shenyang 110001, Liaoning, China; 2Tumor Etiology and Screening Department of Cancer Institute and General Surgery, The First Affiliated Hospital of China Medical University, 155# North Nanjing Street, Heping District, Shenyang 110001, Liaoning Province, China; 3Department of Biomedical Engineering, School of Fundamental Sciences, China Medical University, Shenyang 110122, Liaoning Province, China; 4China Medical University - The Queen’s University of Belfast Joint College, China Medical University, Shenyang 110122, Liaoning Province, China; 5No. 10 Middle School, Xiangyang 441021, Hubei Province, China Received August 31, 2020; Accepted February 7, 2021; Epub May 15, 2021; Published May 30, 2021 Abstract: Background: Glioblastoma (GBM) is an aggressive brain tumor and the mechanisms of progression are very complex. Accelerated aging is a driving factor of GBM. However, there has not been thorough research about the mechanisms of GBM progression based on aging acceleration. Methods: The aging predictor was modeled based on normal brain samples. Then an aging acceleration background network was constructed to explore GBM mechanisms. Results: The accelerated aging-related mechanisms provided an innovative way to study GBM, where- in integrative analysis of somatic mutations and differential expression revealed key pathologic characteristics. Moreover, the influence of the immune system, the nervous system and other critical factors on GBM were identi- fied.
[Show full text]
Single-Stranded DNA-Binding Proteins Regulate the Abundance of LIM Domain and LIM Domain-Binding Proteins
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by DigitalCommons@The Texas Medical Center Single-stranded DNA-binding proteins regulate the abundance of LIM domain and LIM domain-binding proteins Zhixiong Xu,1 Xianzhang Meng,1 Ying Cai,1 Hong Liang,2 Lalitha Nagarajan,2 and Stephen J. Brandt1,3,4,5,6,7 1Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232, USA; 2Department of Molecular Genetics, Program in Genes and Development, Graduate School of Biomedical Sciences, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA; 3Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; 4Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA; 5Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37232, USA; 6VA Tennessee Valley Healthcare System, Nashville, Tennessee 37212, USA The LIM domain-binding protein Ldb1 is an essential cofactor of LIM-homeodomain (LIM-HD) and LIM-only (LMO) proteins in development. The stoichiometry of Ldb1, LIM-HD, and LMO proteins is tightly controlled in the cell and is likely a critical determinant of their biological actions. Single-stranded DNA-binding proteins (SSBPs) were recently shown to interact with Ldb1 and are also important in developmental programs. We establish here that two mammalian SSBPs, SSBP2 and SSBP3, contribute to an erythroid DNA-binding complex that contains the transcription factors Tal1 and GATA-1, the LIM domain protein Lmo2, and Ldb1 and binds a bipartite E-box-GATA DNA sequence motif. In addition, SSBP2 was found to augment transcription of the Protein 4.2 (P4.2) gene, a direct target of the E-box-GATA-binding complex, in an Ldb1-dependent manner and to increase endogenous Ldb1 and Lmo2 protein levels, E-box-GATA DNA-binding activity, and P4.2 and ␤-globin expression in erythroid progenitors.
[Show full text]
Integrated Genome and Transcriptome Analyses Reveal the Mechanism of Genome Instability in Ataxia with Oculomotor Apraxia 2
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.07.443085; this version posted May 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Integrated Genome and Transcriptome Analyses Reveal the Mechanism of Genome Instability in Ataxia with Oculomotor Apraxia 2 Radhakrishnan Kanagaraj1*, Richard Mitter2, Theodoros Kantidakis3, Matthew M. Edwards4, Anaid Benitez1, Probir Chakravarty2, Beiyuan Fu5, Olivier Becherel6, Fengtang Yang5, Martin F. Lavin6, Amnon Koren4, Aengus Stewart2 and Stephen C. West1,7 * 1 DNA Recombination and Repair Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK 2 Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK 3 Aston Medical School, Aston University, BirminGham B4 7ET, UK 4 Department of Molecular BioloGy and Genetics, Cornell University, Ithaca NY14853, USA 5 Wellcome SanGer Institute, Wellcome Trust Genome Campus, Hinxton, CambridGe CB10 1SA, UK 6 The University of Queensland Centre for Clinical Research, Herston, Queensland 4029, Australia *Co-correspondinG authors: 7Lead contact: tel +(44)-203-7962071; e-mail: [email protected] RunninG title: Transcription stress causes AOA2 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.07.443085; this version posted May 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Mutations in the SETX gene, which encodes Senataxin, are associated with the progressive neurodegenerative diseases Ataxia with Oculomotor Apraxia 2 (AOA2) and Amyotrophic Lateral Sclerosis 4 (ALS4).
[Show full text]
Adenoviral Oncoprotein E1B55K Mediates Colocalization of SSBP2
Fleisig et al. Journal of Molecular Signaling 2010, 5:6 http://www.jmolecularsignaling.com/content/5/1/6 RESEARCH ARTICLE Open Access AdenoviralResearch article oncoprotein E1B55K mediates colocalization of SSBP2 and PML in response to stress Helen B Fleisig, Hong Liang and Lalitha Nagarajan* Abstract Transient expression of adenoviral oncoprotein E1B55K in normal cells induces aggresome formation and sequestration of critical host proteins in aggresomes. Our previous studies reported that Sequence Specific Binding Protein 2 (SSBP2), a candidate tumor suppressor is recruited to aggresomes in adenovirally transformed human embryonal kidney 293 (HEK293) cells. To understand the extent and significance of the E1B55K-SSBP2 interactions in these cells, we have examined SSBP2 localization under conditions of stress in HEK293 cells. SSBP2 localizes to PML- Nuclear Bodies (PML-NBs) in response to inhibition of nuclear export, treatment with etoposide, hydroxyurea or gamma irradiation only in HEK293 cells. Furthermore, the PML-NBs grow in size and number in response to radiation over a 24 hour period in HEK293 cells analogous to previous findings for other cell types. Nonetheless, we conclude that E1B55K subverts SSBP2 function in HEK293 cells. These findings demonstrate the limitations in using HEK293 cells to study DNA damage response and other cellular processes since SSBP2 and similar regulatory proteins are aberrantly localized due to constitutive E1B55K expression. Introduction closely related member SSBP3, is also mediated by phos- Sequence-specific single-stranded DNA binding protein 2 phorylation of a conserved amino terminal Tyr residue, (SSBP2) was originally isolated as a candidate leukemia independent of the LDB1 interaction [7]. suppressor gene from chromosome 5q13.3 that is dis- HEK293, a cell line routinely used for transient gene rupted in the human acute myelogenous leukemia (AML) expression because of its high transfection efficiency, was cell line ML3 [1].
[Show full text]
Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Proﬁbrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
[Show full text]
An Rnai Screen for Aire Cofactors Reveals a Role for Hnrnpl in Polymerase Release and Aire-Activated Ectopic Transcription
An RNAi screen for Aire cofactors reveals a role for Hnrnpl in polymerase release and Aire-activated ectopic transcription Matthieu Girauda,b, Nada Jmarib, Lina Dua, Floriane Carallisb, Thomas J. F. Nielandc, Flor M. Perez-Campod, Olivier Bensaudee, David E. Rootc, Nir Hacohenc, Diane Mathisa,1, and Christophe Benoista,1 aDivision of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; bDepartment of Immunology, Institut Cochin, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016, Université Paris Descartes, 75014 Paris, France; cThe Broad Institute of MIT and Harvard, Cambridge, MA 02142; dDepartment of Internal Medicine, Hospital U.M. Valdecilla-Instituto de Formación e Investigación Marqués de Valdecilla, University of Cantabria, 39008 Santander, Spain; and eEcole Normale Supérieure, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8197, INSERM U1024, 75005 Paris, France Contributed by Christophe Benoist, December 19, 2013 (sent for review December 3, 2013) Aire induces the expression of a large set of autoantigen genes in Aire primarily impacts the elongation steps of transcription, in the thymus, driving immunological tolerance in maturing T cells. particular by releasing promoter-bound polymerases that remain To determine the full spectrum of molecular mechanisms underlying paused after abortive initiation (8, 9). Correspondingly, Aire has the Aire transactivation function, we screened an AIRE-dependent been shown to interact with subunits of the key controller of gene-expression system with a genome-scale lentiviral shRNA polymerase release, the positive transcription elongation factor library, targeting factors associated with chromatin architecture/ b (P-TEFb) (8, 10, 11). P-TEFb is recruited to stalled initiation function, transcription, and mRNA processing.
[Show full text]